AVEO's RON antibody shows anti-tumor activity in human cancer xenografts
 

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RON?160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

More...